News Attraction
Remdesivir drug is still Under Clinical Trial in the Philippines —DOH
REMDESIVIR- a drug that gained authorization from Japan and the US for the treatment of COVID-19, is part of the ...
Cayetano Breaks Silence as he Release Statement On ABS-CBN Shutdown
House Speaker Alan Peter Cayetano breaks silence after he finally gave a statement regarding the closure of the ABS-CBN network. ...
US Shows ‘Concerned’ over Philippine Top Broadcaster Shutdown
The United States voiced concern over the Philippine government that ordered a shutdown to the country’s top broadcaster ABS-CBN on ...
27 more Frontliners Positive for COVID-19; Recoveries reach 403
The Department of Health (DOH) reported 27 new cases of the coronavirus disease (COVID-19) involving healthcare workers, which brings the total to ...
Israeli Scientist Developed an Antidote to fight Against COVID-19 Pandemic
The Defense Minister Naftali Bennett of Israel visited on Monday the Israel Institute for Biological Research (IIBR) in Ness Ziona, ...
Loyal Kapamilya Viewer Smashes TV Due to Network Signs Off
Viral now on social media the video of a loyal viewer of Kapamilya network ABS-CBN when he destroys there television ...
DOH- Japan’s Anti-flu drug ‘Avigan’ to be Given on 100 COVID-19 Patients in the Philippines
At least 100 COVID-19 patients in the Philippines will be given the anti-flu drug Avigan from Japan as part of ...
Palace: 11,000 Displaced Workers of ABS-CBN may be Included in Govt aid for SMEs
The employees of ABS-CBN that were displaced due to its network shut down may be included in the government’s financial ...
Panelo Says Duterte Has Nothing To Do with The Decision of the NTC
NTC- Chief Presidential Legal Counsel Salvador Panelo clarifies that the President Rodrigo Duterte has nothing to do with the decision ...
Celebrities React to ABS-CBN Being Ordered to Close TV, Radio Operations
As the National Telecommunications Commission ordered ABS-CBN on Tuesday to stop its radio and TV operations, entertainment personalities joined a ...
